Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases

Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion, giving the Big Pharma company the chance to disco...